Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221648 · ClinicalTrials.gov registry record · Phase 2
Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02221648 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 43 participants.
The verdict
NCT02221648, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The scientific aim of this study is to investigate the efficacy of abobotulinumtoxinA (Dysport - Ipsen Pharmaceuticals) in chronic low back pain. The investigators hypothesis is that injection of Dysport brand of botulinum toxin type A into erector spinae muscles (extensors of the spine) can relieve low back pain through anti-spasm and analgesic effect of botulinum toxin.
Interventions
- DRUG Placebo
- DRUG AbobotulinumtoxinA Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02221648
The ClinicalTrials.gov registry entry for NCT02221648 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02221648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02221648 about?
NCT02221648 is a clinical study titled "Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain". The scientific aim of this study is to investigate the efficacy of abobotulinumtoxinA (Dysport - Ipsen Pharmaceuticals) in chronic low back pain. The investigators hypothesis is that injection of Dysport brand of botulinum toxin type A into erector spinae muscles (extensors of the spine) can reliev...
What is the current status of trial NCT02221648?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2012-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02221648?
The interventions under investigation include: Placebo (DRUG), AbobotulinumtoxinA Treatment (DRUG).
Who is sponsoring clinical trial NCT02221648?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.